Today

Agents

Chat

Arena

Discover

More

App

GSK's mRNA flu vaccine moves into Phase III testing - GSK News | Rallies

GSK's mRNA flu vaccine moves into Phase III testing

GSK•2026-09-01

mRNA flu vaccine candidate advances to Phase III

Sept. 1 (Reuters) - GSK plc GSK.L:

GSK PLC - mRNA flu vaccine candidate to advance to Phase III
GSK PLC - mRNA flu vaccine candidate to advance to Phase III
GSK: Phase III trial to start in September 2026
GSK: Phase III trial to start in September 2026
GSK: vaccine candidate designed to target two primary surface antigens that cause flu viruses to bind and spread
GSK: vaccine candidate designed to target two primary surface antigens that cause flu viruses to bind and spread

Related News

Aedifica H1 FY26 EPRA earnings jump 54% to €189.9 million; rental income rises 62% to €292.3 million

XLRE•2026-09-01

Nasdaq trade halt continues <MCTA.O> reason not available at 03:58 am

MCTA•2026-09-01

Global economy-Global AI boom fuels Asia factory expansion in August

SOXX

•

2026-09-01

Cohen & Steers fund manager discloses 2.93% stake in Prologis

PLD•2026-09-01

Analysts react to global bond selloff

TLT•2026-09-01